Your shopping cart is currently empty

Bay 60-7550 is a selective and potent PDE2 inhibitor (Ki: 3.8 nM) that exerts positive inotropic effects on rat heart by increasing PKA-mediated phosphorylation and can be used to ameliorate cognitive impairments and memory disorders.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $108 | - | In Stock |
| Description | Bay 60-7550 is a selective and potent PDE2 inhibitor (Ki: 3.8 nM) that exerts positive inotropic effects on rat heart by increasing PKA-mediated phosphorylation and can be used to ameliorate cognitive impairments and memory disorders. |
| Targets&IC50 | PDE2:3.8±0.2 nM (Ki) |
| In vitro | The anti-proliferative effect of BAY 60-7550 (1 μM) is pronounced, with a significant decrease in proliferation observed in PASMCs from IPAH patients compared to untreated control cells[2]. |
| In vivo | Administration of the PDE2 inhibitors Bay 60-7550 (0.5, 1, and 3 mg/kg) or ND7001 (1 mg/kg), or the NO donor detanonoate (0.5 mg/kg), antagonized the anxiety-like behavior induced by restraint stress in mice [1]. |
| Synonyms | BAY 607550 |
| Molecular Weight | 476.57 |
| Formula | C27H32N4O4 |
| Cas No. | 439083-90-6 |
| Smiles | COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC |
| Relative Density. | 1.24 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/mL (62.95 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.2 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.